A facility doesn't lower risk by buying something that merely looks like an emergency device. It lowers risk by buying a product it can verify, trace, train on, and defend after an incident.
That distinction matters much more in 2026. The UK MHRA warned in Device Safety Information DSI/2024/003 that counterfeit and unbranded anti-choking devices may fail to work correctly or may worsen a choking incident. The notice says those products should not be used once identified as counterfeit or non-compliant, and it warns that poor design and quality may push an obstruction further down the airway.
The FDA's March 4, 2026 safety communication draws the same line from the U.S. side. Established choking rescue protocols still come first. An authorized anti-choking device may be used only as a second option after standard protocols are unsuccessful. The same communication also lists reported problems such as lack of suction, facial bruising, oral injury, and setup time that may delay established rescue steps.
Procurement changed the moment those warnings became this explicit. Facilities are no longer choosing between 'having something' and 'having nothing.' They are choosing whether the product entering the emergency workflow can actually be trusted when seconds are already being lost.
A counterfeit device is not dangerous because it looks cheap. It is dangerous because visual similarity can hide functional failure.
A product can copy the bellows shape, copy the mask silhouette, copy the packaging logic, and copy the marketing language while failing at the one moment that matters. The MHRA warning does not frame this as branding confusion. It frames it as a patient-safety problem tied to non-compliance, poor design, and the possibility of worsening the obstruction itself.
This belongs in facility governance, not only in supply purchasing. A counterfeit rescue device is not a bargain version of the same thing. It inserts an uncontrolled failure path into an airway emergency.
The engineering issue is not whether the device creates movement. The issue is whether airflow is controlled in the correct direction.
The FDA's March 2026 De Novo order for the authorized device category defines 21 CFR 874.5400 as a suction anti-choking device intended for second-line treatment after unsuccessful use of a basic life support choking protocol. The special controls focus on clinically meaningful questions: how often the device is used only after unsuccessful BLS, whether it delays BLS, how often it resolves choking, and what injuries or malfunctions occur.
Counterfeit copies bypass that discipline. A compliant category is evaluated around suction behavior, delay risk, adverse events, and real-world use conditions. A fake copy can imitate the form while failing the function.
From our perspective on the Fitiger engineering and product safety team, procurement teams need to get much stricter here. A rescue product should not enter a facility merely because it looks familiar or appears on a major marketplace. Airflow control, seal quality, materials, traceability, labeling, and regulatory status all need to be verified before the product enters training, storage, or response use.
A lot of counterfeit-device risk enters through lazy procurement habits. A buyer needs units quickly. A listing looks similar. The price is lower. Reviews look good enough. The order gets placed because the device feels close enough to the regulated category.
That logic fails in emergency procurement.
The MHRA specifically advises buyers to purchase only from reputable sellers, verify whether a manufacturer is legitimately registered, be cautious of fake reviews, and treat suspect products as unsafe for emergency use. It also recommends disposal rather than return once a device is confirmed counterfeit, because returning it may place it back into circulation.
The FDA makes a related point in the U.S. context. Its March 2026 communication explicitly says establishment registration and device listing do not mean a device is approved, cleared, or authorized. The same page notes an October 8, 2025 import alert covering multiple suction anti-choking devices not authorized for U.S. distribution.
Database presence is not the same as authorization. Marketplace availability is not the same as compliance.
A procurement team should be able to answer five questions before any anti-choking device enters a facility.
First, what is the exact regulatory status in the country where the device will be used? In the U.S., the FDA said on March 4, 2026 that one anti-choking device had been authorized for marketing and distribution. In the UK, the MHRA warning stated it was aware of only two anti-choking device brands registered under the UK Medical Devices Regulations at the time of that notice.
Second, can the manufacturer and seller chain be verified? A facility should know whether it bought directly from the legal manufacturer or through an authorized distributor whose status can be checked.
Third, can the device be traced in an audit? A facility should be able to produce the invoice, the product identifier, the lot or serial information, and the vendor chain without guessing.
Fourth, has the team separated marketing language from official status? That question matters because status can change, claims can be misleading, and old screenshots are not compliance evidence. The FDA's September 18, 2025 warning letter to LifeVac and the later March 4, 2026 close-out context are exactly the kind of sequence that shows why procurement teams must verify current official status instead of relying on sales language or outdated assumptions.
Fifth, can the facility explain why it selected this device over lower-cost alternatives? That answer should be written down before any incident happens, not reconstructed afterward.
This is not legal advice. It is a risk-control point.
When a facility buys emergency equipment, it is creating a defendable or indefensible record. The bigger the gap between what the product claims and what the facility can verify, the harder that record becomes to defend after an incident.
Counterfeit and unbranded anti-choking devices create exactly that gap. The MHRA has already said these products may fail or worsen choking. The FDA has already said unauthorized anti-choking devices raise unresolved safety and effectiveness concerns and may delay established rescue steps. The question is no longer 'Was there a product in the building?' The question becomes 'Why did this product enter the response system at all?'
A facility should be able to produce a due-diligence file that includes the reason the category was adopted, the regulatory basis for the specific product, the source and chain of purchase, the traceability record, the training record for expected users, and the process for recall monitoring or replacement. If those records do not exist, the facility is trusting memory to do the work of governance.
A facility that wants to buy responsibly should follow a very plain sequence.
Verify the jurisdiction first. Confirm what counts as authorized, registered, or compliant where the device will actually be used. Use regulator sources, not product pages.
Verify the seller chain next. Buy through the legal manufacturer or a distributor whose relationship to that manufacturer can be checked.
Verify traceability. Require documentation that survives an audit, not just packaging that looks convincing.
Verify training fit. The exact product bought should be the exact product trained on. A facility should never train staff on one version and deploy another.
Verify rejection criteria in advance. Missing identifiers, unverifiable origin, inconsistent labeling, or unexplained design differences should be automatic stop conditions.
Then connect procurement to the emergency workflow. If the product cannot be defended on paper, it should not be placed in the response system.
That is not bureaucracy. It is what stops a life-safety purchase from becoming a liability story later.
The right place for Fitiger in this conversation is not 'trust us because we are a brand.'
A real emergency device should be easy to verify, easy to trace, and easy to place inside a documented response system.
From our perspective on the Fitiger engineering and product safety team, no facility should accept counterfeit or unverifiable second-line rescue products into a life-safety workflow. A device that cannot be defended on engineering, regulatory, and documentation grounds is not a budget option. It is a hidden risk multiplier.
Fitiger should sit inside a procurement file the same way it should sit inside a response workflow: with clear documentation, clear role fit, and clear boundaries. Standard choking rescue protocols come first. A second-line device supports the system. It does not replace it.
Why is a counterfeit anti-choking device more dangerous than a normal low-quality product?
Because the failure happens inside a time-critical airway emergency. Regulators have already warned that counterfeit and unbranded devices may fail to work or may worsen choking by pushing the obstruction deeper.
Does FDA registration or device listing mean the product is authorized?
No. The FDA explicitly says establishment registration and device listing do not mean approval, clearance, or authorization.
What is the correct U.S. framework in 2026?
Established choking rescue protocols come first. An authorized anti-choking device may be used only as a second option after standard protocols are unsuccessful. The authorized device category is regulated under 21 CFR 874.5400 as a Class II suction anti-choking device intended for second-line treatment.
What should a facility do if it suspects it bought a counterfeit device?
Stop treating it as emergency-ready equipment, verify it against official manufacturer and regulator information, quarantine it from use, and follow the regulator's reporting or disposal guidance.
The dangerous procurement mistake is not only buying the wrong product.
It is buying a product that looks close enough, costs less, arrives fast, and enters a life-safety workflow without anyone proving what it is.
In 2026, that standard is no longer good enough.
Facilities need more than equipment. They need a purchase file, a verification process, a training record, and a documented reason the device was trusted in the first place.
That is how emergency procurement stops being hopeful and starts being defensible.
MHRA Device Safety Information DSI/2024/003
FDA Safety Communication, updated March 4, 2026
FDA Warning Letter to LifeVac, 713455
This article is for educational, operational, and procurement-awareness purposes only. It is not legal advice and does not replace regulator guidance, facility policy, clinical judgment, or legal counsel. Facilities should verify jurisdiction-specific regulatory requirements before purchasing or deploying emergency medical devices.
